Axonics, Inc. (NASDAQ:AXNX) Shares Sold by Whittier Trust Co.

Whittier Trust Co. decreased its holdings in Axonics, Inc. (NASDAQ:AXNX) by 37.1% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 718 shares of the company’s stock after selling 424 shares during the quarter. Whittier Trust Co.’s holdings in Axonics were worth $48,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. NBC Securities Inc. grew its position in Axonics by 106.4% during the 4th quarter. NBC Securities Inc. now owns 673 shares of the company’s stock worth $41,000 after purchasing an additional 347 shares in the last quarter. Headlands Technologies LLC purchased a new position in Axonics during the 4th quarter worth approximately $53,000. Inspirion Wealth Advisors LLC purchased a new position in Axonics during the 1st quarter worth approximately $207,000. Janney Montgomery Scott LLC purchased a new position in Axonics during the 1st quarter worth approximately $218,000. Finally, Brown Brothers Harriman & Co. grew its position in Axonics by 33.1% during the 4th quarter. Brown Brothers Harriman & Co. now owns 3,580 shares of the company’s stock worth $223,000 after purchasing an additional 890 shares in the last quarter. Institutional investors and hedge funds own 99.48% of the company’s stock.

Axonics Price Performance

Axonics stock opened at $69.10 on Friday. The company’s fifty day simple moving average is $68.22 and its 200-day simple moving average is $67.83. Axonics, Inc. has a 12 month low of $48.30 and a 12 month high of $69.68. The stock has a market cap of $3.53 billion, a P/E ratio of -215.94 and a beta of 0.83.

Axonics (NASDAQ:AXNX) last posted its earnings results on Thursday, August 1st. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.10 by $0.03. The firm had revenue of $114.57 million for the quarter, compared to the consensus estimate of $112.83 million. Axonics had a negative net margin of 0.42% and a negative return on equity of 0.27%. The business’s quarterly revenue was up 23.3% on a year-over-year basis. During the same period in the prior year, the business posted ($0.15) earnings per share. On average, equities research analysts expect that Axonics, Inc. will post 0.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC restated a “hold” rating on shares of Axonics in a report on Monday, August 5th. Eight analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, Axonics currently has an average rating of “Hold” and a consensus target price of $69.57.

Axonics Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.